Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22650639 | 0.84 | ALDH1A1 (0.34) | PDE4DALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL31071988 | 0.77 | NPC1 (0.40) | PDE4DALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL21767736 | 0.77 | NPC1 (0.40) | PDE4DALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL31071972 | 0.74 | PDE4D (0.35) | PDE4DALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL21780641 | 0.73 | PGK1 (0.40) | ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL31071938 | 0.72 | HTR2A (0.33) | — | |
| SCHEMBL28566097 | 0.72 | ALDH1A1 (0.32) | PDE4DALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL21767489 | 0.72 | TAS1R3 (0.41) | ALDH1A1HPGD | |
| SCHEMBL31072041 | 0.71 | PSMB11 (0.35) | PDE4DALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL21780640 | 0.71 | HTR2A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PDE4D 2273/4885ALDH1A1 1504/4885MAPT 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.